French active ingredients maker Solabia has acquired a majority stake in BioActor.
Founded in 2011 and located on the Maastricht Health Campus in the Netherlands, BioActor specialises in polyphenols extracted from edible plants and fruits for use in supplements.
According to Solabia, this investment will allow it to strengthen its position in the nutraceuticals space, support its focus on R&D and product development, as well as expanding its production capabilities.
BioActor’s founder and boss, Hans van der Saag, will retain a minority share and remain in the role of CEO.
“BioActor’s pioneering R&D, impressive clinical research capabilities, market leading product portfolio and established customer base will allow us to further strengthen our position in the nutrition and food supplement markets,” said Jean-Baptiste Dellon, CEO of Solabia.
“We are looking forward to working with BioActor to enhance growth for current product portfolio and accelerate the development of new ingredients.”
Van der Saag, meanwhile, called the acquisition “an important step towards realising our mission to bring unique and clinically evaluated health ingredients to consumers worldwide”.
